At the National Children's Medical Center in Shanghai, a 6-month-old infant diagnosed with a malignant testicular tumor was successfully treated using the SHURUI® single-port surgical robot. This marked the 20th clinical procedure since the pediatric urology team at Shanghai Children's Medical Center adopted the domestically developed robotic platform earlier this year.
With just a 2.5 cm umbilical incision, the team precisely removed the tumor using snake-like instruments and 3D imaging guidance—minimizing trauma and preventing hematogenous spread. Total blood loss was under 3 ml, and the patient resumed normal activity within 24 hours.
The SHURUI® system offers sub-millimeter precision in exceptionally narrow surgical fields. With over a dozen pediatric procedure types explored in clinical studies, the platform is shaping a China-led solution for robotic surgery in children.
Shanghai Children's Medical Center is now expanding training infrastructure and national outreach to broaden access to safer, ultra-minimally invasive care for pediatric patients.
Important Notes
The Single-port Endoscopic Surgical System (SR-ENS-600), developed and produced by Beijing Surgerii Robotics Company Limited, has been approved by the National Medical Products Administration (NMPA) in China for urology and gynecology laparoscopic surgeries. Surgeons who wish to learn the surgical operations of the SHURUI robot should contact Beijing Surgerii Robotics Co., Ltd. to participate in the official training program. Patients who want to participate in the registered clinical trials of the SHURUI robot should contact the official cooperative hospitals of Surgerii and consult with surgeons to determine their suitability for surgery with the SHURUI robot. Both surgeons and patients should carefully understand all information regarding the performance of surgeries by the SHURUI robot and its potential risks.
Beijing Surgerii Robotics Co., Ltd. owns Surgerii®, SHURUI®, and other
trademarks and may not be used without permission.
